Overview

A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical activity of BKM120 in patients with metastatic triple-negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
SOLTI Breast Cancer Research Group
Collaborators:
Dana-Farber Cancer Institute
Novartis Pharmaceuticals
Stand Up To Cancer